Preexisting and de novo humoral immunity to SARS-CoV-2 in humans
Citations Over TimeTop 1% of 2020 papers
Abstract
Zoonotic introduction of novel coronaviruses may encounter preexisting immunity in humans. Using diverse assays for antibodies recognizing SARS-CoV-2 proteins, we detected preexisting humoral immunity. SARS-CoV-2 spike glycoprotein (S)-reactive antibodies were detectable using a flow cytometry-based method in SARS-CoV-2-uninfected individuals and were particularly prevalent in children and adolescents. They were predominantly of the immunoglobulin G (IgG) class and targeted the S2 subunit. By contrast, SARS-CoV-2 infection induced higher titers of SARS-CoV-2 S-reactive IgG antibodies targeting both the S1 and S2 subunits, and concomitant IgM and IgA antibodies, lasting throughout the observation period. SARS-CoV-2-uninfected donor sera exhibited specific neutralizing activity against SARS-CoV-2 and SARS-CoV-2 S pseudotypes. Distinguishing preexisting and de novo immunity will be critical for our understanding of susceptibility to and the natural course of SARS-CoV-2 infection.
Related Papers
- → SARS-CoV-2: from herd immunity to hybrid immunity(2022)52 cited
- → Herd Immunity(2019)49 cited
- → Estimating contact-adjusted immunity levels against measles in South Korea and prospects for maintaining elimination status(2019)11 cited
- → Contact-adjusted Immunity Levels against SARS-CoV-2 in Korea and Prospects for Achieving Herd Immunity(2021)4 cited
- Characteristics of hepatitis A outbreak and effect of "herd immunity barrier" in population with high immunity(1992)